Vascepa is a prescription medication that contains icosapent ethyl, which is an omega-3 fatty acid. It is used to reduce the risk of cardiovascular events such as heart attack and stroke in certain adult patient groups. The FDA has approved Vascepa for use in reducing cardiovascular risk in adults with established cardiovascular disease, as well as in adults with elevated triglyceride levels and other risk factors for cardiovascular disease [2].

According to the manufacturer's website, Vascepa has been shown to significantly reduce the risk of cardiovascular events in patients with elevated triglyceride levels and other risk factors for cardiovascular disease [3]. It is important to note that Vascepa is not a substitute for a healthy lifestyle, and patients should continue to follow a healthy diet and exercise regularly.

One study published in the New England Journal of Medicine found that Vascepa reduced the risk of cardiovascular events by 25% in patients with elevated triglyceride levels and other risk factors for cardiovascular disease [3]. Another study found that Vascepa reduced the risk of cardiovascular events by 30% in patients with established cardiovascular disease [3].

Overall, the evidence suggests that Vascepa is effective in reducing the risk of cardiovascular events in certain adult patient groups. However, as with any medication, it is important for patients to discuss the potential benefits and risks of treatment with their healthcare provider.

Sources:
[2] FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups. Accessed September 21, 2021.
[3] Cardiovascular Risk. Vascepa. https://www.vascepa.com/cardiovascular-risk/diabetes-and-heart-disease/. Accessed September 21, 2021.